Pharmabiz

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psorias ...

Johnson & Johnson: FDA approval of ICOTYDE (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...
GOBankingRates on MSN

This rare bicentennial quarter has nearly $20K value — plus 7 more worth thousands

People of a certain generation will remember the year-long bicentennial celebration of 1976, when the United States ...
EuropaWire

Pearson and Tata Consultancy Services Partner to Deliver AI Driven Workforce Transformation and Enterprise Learning at Scale

Pearson and Tata Consultancy Services have formed a multi-year partnership to help enterprises develop future-ready workforces by combining AI-powered learning, assessment, and cloud-based ...